Mr.Hotsia Travel with Health

How does copper metabolism disorder contribute to fatty liver, as seen in Wilson’s disease, and how do chelation therapies compare with supportive treatments?

How Copper Metabolism Disorder Contributes to Fatty Liver

Copper metabolism disorder, most notably in the genetic condition Wilson’s disease, directly contributes to the development of fatty liver, or hepatic steatosis, through the toxic accumulation of copper within liver cells. Wilson’s disease is caused by a mutation in the ATP7B gene, which is responsible for producing a protein that transports copper. This mutation leads to an inability to excrete excess copper into bile, the primary route of elimination from the body. Consequently, copper begins to build up in the liver, reaching toxic levels. This excessive copper acts as a potent pro-oxidant, generating harmful reactive oxygen species (ROS) and inducing severe oxidative stress. This oxidative stress damages cellular components, including lipids, proteins, and DNA, and impairs mitochondrial function. The damage to mitochondria, the powerhouses of the cell, disrupts the normal process of fatty acid oxidation. When the liver cannot properly break down fatty acids, they begin to accumulate within hepatocytes (liver cells) as triglycerides, leading to a fatty liver. This steatosis can progress to more severe forms of liver disease, including steatohepatitis (inflammation of a fatty liver), fibrosis, cirrhosis, and even liver failure. The accumulation of copper also triggers an inflammatory response, with inflammatory cytokines being released that further contribute to liver cell injury and the progression of fatty liver to more severe forms of liver disease.

💊 Chelation Therapies vs. Supportive Treatments

The treatment of fatty liver in the context of copper metabolism disorders, particularly Wilson’s disease, is primarily centered on chelation therapies, with supportive treatments playing a secondary, though important, role. Chelation therapies are the first-line and definitive treatment because they directly address the root cause of the disease: the excess copper. Drugs like D-penicillamine and trientine are chelating agents that bind to the toxic copper in the body and facilitate its excretion in the urine. This process effectively removes the primary source of liver injury, halting the progression of the disease and often allowing for a reversal of liver damage, including the fatty liver. The effectiveness of chelation therapy is well-documented in clinical studies. Patients who are started on these therapies in the early stages of the disease, before significant liver scarring has occurred, often see a significant improvement in their liver function tests, a reduction in the fat content of their liver, and a normalization of their copper levels.

In contrast, supportive treatments do not address the underlying copper issue. These therapies are often focused on managing the symptoms and consequences of the liver disease. For a patient with a fatty liver due to Wilson’s disease, supportive treatments would include lifestyle modifications, such as a low-fat diet, regular exercise, and abstinence from alcohol. While these measures are beneficial for general liver health and can help manage the fat content of the liver, they are entirely insufficient on their own to stop the progression of copper-induced liver damage. They serve as an adjunct to chelation therapy, not a replacement. For example, a patient with Wilson’s disease on chelation therapy might also be advised to follow a healthy diet to reduce the fat in their liver, which can enhance the overall therapeutic effect and improve patient outcomes. However, relying solely on supportive treatments would allow the toxic copper to continue accumulating, leading to irreversible liver damage and ultimately liver failure. In some severe cases of Wilson’s disease with advanced liver failure, the only definitive treatment is a liver transplant, highlighting the critical importance of early and aggressive chelation therapy over supportive measures alone. Therefore, the key difference is that chelation therapy is a curative, disease-modifying treatment that targets the core problem, while supportive treatments are symptomatic and can only help manage the consequences of the disease.

I’m Mr.Hotsia, sharing 30 years of travel experiences with readers worldwide. This review is based on my personal journey and what I’ve learned along the way. I share my experiences on www.hotsia.com